Document:

exv10w5

Exhibit 10.5

CONFIDENTIAL SETTLEMENT AGREEMENT

AND GENERAL MUTUAL RELEASE

     This Confidential Settlement Agreement and General Mutual Release (“Settlement Agreement” or
“Agreement”) is entered into this 19th day of March 2009, by and between: (i) National Laser
Technology, Inc. (“NLT” or “Plaintiff”) and (ii) Biolase Technology, Inc. (“Biolase” or
“Defendant”). NLT and Biolase may be referred to individually in the Agreement as “Party” and
collectively as “Parties.”

RECITALS

	A.	 	NLT filed a Complaint on August 20, 2008, in the United States District Court for the
Southern District of Indiana (“Court”), Civil Action No.: 08-CV-1123 (the “Lawsuit”), and an
Amended Complaint, filed December 23, 2008, alleging, among other things, that Biolase made
false statements to dentists concerning NLT’s sale of used Biolase dental lasers (“Lasers”),
and refused to sell laser tips and other parts to dentists if they did business with NLT.
	 
	B.	 	Biolase filed Counterclaims on September 12, 2008, and Amended Counterclaims on February 19,
2009, alleging, among other things, that NLT infringed Biolase’s copyright and trademark
rights, made false and misleading statements on its website, and sold and serviced modified
Lasers originally manufactured by Biolase without necessary pre-market approvals by the United
States Food & Drug Administration (“FDA”).
	 
	C.	 	Biolase denies the allegations set forth in the Complaint and Amended Complaint, and NLT
denies the allegations set forth in the Counterclaims and Amended Counterclaims.
	 
	D.	 	NLT filed a motion for a preliminary injunction on October 21, 2008, seeking, among other
things, to enjoin Biolase from refusing to sell laser tips and other parts to dentists that do
business with NLT, or making threats to that effect.
	 
	E.	 	Biolase filed a cross motion for a preliminary injunction on November 24, 2008, seeking,
among other things, to enjoin NLT from infringing Biolase trademarks, making certain
statements on its website, and selling modified Biolase Lasers.
	 
	F.	 	The Parties’ respective motions for preliminary injunction have been fully briefed and an
evidentiary hearing has been scheduled for March 23, 2009. The Court has not yet ruled on
either motion.
	 
	G.	 	NLT and Biolase mutually now wish to resolve, settle, release, and compromise all claims,
potential claims, defenses and counterclaims that they may have against each other.

 

 

          NOW, THEREFORE, in consideration of the foregoing and the promises and covenants contained in
this Agreement, and for other good and valuable consideration, NLT and Biolase intending to be
legally bound, hereby agree as follows.

1.0 DEFINITIONS

	 	1.1.	 	The term “NLT” means National Laser Technology, Inc., the plaintiff in the Lawsuit,
and includes its affiliates, parents, subsidiaries, owners, successors, employees,
officers, directors, agents, representatives, attorneys and assigns. NLT also means AMD
Lasers, LLC and includes its affiliates, parents, subsidiaries, owners, successors,
employees, officers, directors, agents, representatives, attorneys and assigns.
	 
	 	1.2.	 	The term “Biolase” means Biolase Technology, Inc., the defendant in the Lawsuit, and
includes its affiliates, parents, subsidiaries, owners, successors, employees, officers,
directors, agents, representatives, attorneys and assigns.
	 
	 	1.3.	 	The term PPS Module means the modification that NLT made to Biolase Waterlase lasers
that enabled the dentist to program different variable pulses. NLT did not seek
pre-market approval from the FDA for this modification prior to marketing it to its
customers.

2.0 PAYMENT

	 	 	 	For and in consideration of the mutual promises set forth herein, Biolase will pay, or be
responsible to cause its insurance carrier Hartford Fire Insurance Company to pay, to NLT
the sum of SIX HUNDRED FIFTY THREE THOUSAND DOLLARS ($653,000) within 9 days of the
execution of this Settlement Agreement (the “Payment”).

			
	3.0	 	NLT’S PROHIBITION ON SALE, SERVICING, OR TRAINING OF BIOLASE LASERS AND UPGRADES

	 	3.1.	 	NLT agrees that it cannot sell, market or distribute any Biolase Laser or parts that
NLT has modified without first obtaining pre-market approval from the FDA, which NLT has
not done to date.
	 
	 	3.2.	 	Accordingly, NLT will never, directly or indirectly, market or sell any Biolase Laser
parts except for those Biolase Laser parts that are currently in NLT’s inventory which may
be sold to distributors or anyone other than an end-user dentist.

- 2 -

 

	 	3.3.	 	NLT also agrees that, prior to re-selling (directly or indirectly) any Biolase Laser,
it must submit the Laser to Biolase for inspection pursuant to Biolase’s Used Laser Resale
Policy, as may be amended from time to time in Biolase’s sole and absolute discretion, and
pay all of the fees required thereunder for a customer that is trying to sell or purchase
a used Laser and wishes Biolase to provide support for the Laser, except that NLT may
market and sell the seven (7) Waterlase units and seven (7) Waterlase MDs that it
currently has in its possession or has an obligation to purchase without regard to such
Policy. Biolase’s current Used Laser Resale Policy is attached hereto as Schedule 1.
	 
	 	3.4.	 	NLT further agrees that, because it does not have access to the latest Biolase
specifications, it will never offer, sell, or market, directly or indirectly, any training
on any Biolase laser without prior written permission from Biolase, except that any
currently scheduled trainings may proceed as scheduled.
	 
	 	3.5.	 	NLT further agrees that it will never market or sell any modification or upgrade to
any Biolase Laser without first obtaining FDA approval, including but not limited to:

	 	(a)	 	the Detail Kit, plastic replacement case, Quiet Fan Kit, and
PPS Module described in the Supplemental Declaration of Alan Miller (filed in
the Lawsuit at Dkt. #59-2); and
	 
	 	(b)	 	any other upgrade, repair, change or modification.

	 	3.6.	 	If Biolase decides to recall, reconfigure, or remove from the Lasers any of the PPS
Modules sold by NLT, Biolase shall offer to replace the Module for software or a different
Laser with the FDA-cleared equivalent functionality free of charge. Biolase shall perform
any such recall, removal and replacement at its sole expense, at no expense to NLT, and at
no expense to the affected dentist other than as negotiated between Biolase and the
dentist.
	 
	 	3.6.1.	 	Within one (1) business day of the execution of this Agreement, NLT shall provide
Biolase with a list of the last known purchaser and location of any PPS Module that it has
sold, and within two (2) business days of receipt of the Payment, shall inform such
purchaser that Biolase may contact them to replace their Module, using the language in
Exhibit B, or as otherwise has been mutually agreed upon by the Parties. NLT represents
that it sold no more than 98 PPS Modules in the United States and 7 PPS Modules in Japan.
If this representation is inaccurate, NLT agrees to immediately pay Biolase $5,000 for
each additional PPS Module.
	 
	 	3.6.2.	 	At Biolase’s request, NLT shall provide instructions and/or training to Biolase
technicians concerning the proper removal of the PPS Module from a Waterlase unit. NLT
shall indemnify Biolase for any lawsuits or claims based on the PPS Modules that NLT
installed or sold at the time of this Agreement.

- 3 -

 

4.0 SERVICE OF BIOLASE LASERS

	 	4.1.	 	NLT agrees that it cannot service any Biolase Lasers without complying with
applicable FDA regulations, which NLT has not done to date.
	 
	 	4.2.	 	For a period of ten (10) years after execution of this Agreement, NLT agrees not to
compete with Biolase by servicing any Biolase Laser or entering into any contract to
service any Biolase Laser without the prior written permission of Biolase. Thereafter,
NLT agrees that it will not service any Biolase Lasers without first complying with
applicable FDA regulations, including 21 C.F.R. Part 820.
	 
	 	4.3.	 	Further, Biolase shall assume all of NLT’s contracts currently in effect to service
any Biolase Laser, and shall provide the same level of service as required by such
contracts.

	 	4.3.1.	 	NLT shall have the right to retain all funds previously paid pursuant to any such
contract.
	 
	 	4.3.2.	 	NLT represents that the total combined remaining months of service pursuant to such
contracts do not exceed 215.25 service years as of April 1, 2009, that such contracts
are assignable to Biolase, and that the material terms of such contracts are
substantially the same as the equivalent Biolase service contracts. If the
representation regarding the number of service years is inaccurate, NLT agrees to
immediately pay Biolase $2,000 per additional service year.
	 
	 	4.3.3.	 	NLT shall provide a list of all such contracts to Biolase within one (1) business
day after execution of this Agreement, and shall inform the other parties to such
service contracts that Biolase has assumed the service contract within two (2)
business days of receipt of the Payment, using the language in Exhibit B, or as
otherwise has been mutually agreed upon by the Parties. NLT shall be obligated to
provide services to its customers pursuant to its service contracts at its sole cost
and expense, and at no expense to Biolase, until NLT has informed the parties to such
service contracts that Biolase has assumed the contracts.
	 
	 	4.3.4.	 	NLT shall not be obligated to provide further services to its customers pursuant to
its service contracts after NLT has informed the parties to such service contracts
that Biolase has assumed the contracts. But NLT is still obligated to cooperate with
Biolase by, among other things, providing to Biolase any information concerning the
customers related to the services that NLT has provided to its customers. NLT shall
indemnify Biolase for any lawsuits or claims based on servicing that was done by NLT.

5.0 USE OF INTELLECTUAL PROPERTY 

- 4 -

 

	 	5.1.	 	NLT agrees to not publish or use on its website any photograph of any Biolase product
in which Biolase has a copyright interest.
	 
	 	5.2.	 	NLT agrees not to use the terms “AMD Waterlase,” “AMDLase” or similar marks (e.g.,
using “Waterlase” or the suffix “Lase”) in the marketing or sale of any product. This
paragraph shall not prevent NLT from using the mark “AMD Laser” or “AMD Lasers.”
	 
	 	5.3.	 	NLT and Biolase agree to abide by Google’s published trademark policy. NLT and
Biolase further agrees not to use any of the other party’s trademarks as part of Google
AdWords, or any similar program with Google or other search companies.

6.0 NON-DISPARAGEMENT 

	 	6.1.	 	The Parties agree not to make any untrue statements (oral, written, electronic, or
otherwise) concerning the other Party or the other Party’s products or employees, directly
or indirectly. Each Party shall instruct its employees, officers, and directors to abide
by this agreement.
	 
	 	6.2.	 	Without limitation to the above paragraph, Biolase shall not, unless based on
reliable information, affirmatively claim that NLT’s products came from, or were damaged
in, fires, hurricanes, or other disasters.
	 
	 	6.3.	 	Without limitation to the above paragraphs, Biolase shall not tell a dentist that he
or she will not be able to obtain Biolase laser tips or other Biolase parts because they
purchase a product or service from NLT.

7.0 STATEMENTS ON WEBSITE 

	 	7.1.	 	NLT agrees to make the following modifications to its website within two (2) business
days of the execution of this Agreement:

	 	7.1.1.	 	NLT shall add a statement on its website home page that “NLT is not affiliated with
Biolase” or equivalent language, and shall add a statement to make clear that any
“certification” and “inspection” of used Lasers sold by NLT is a self certification
and inspection by NLT. NLT agrees to post these statements using the same sized font
that it currently uses on its website for all statements and representations in text.
	 
	 	7.1.2.	 	NLT shall remove and not re-post any statements to the effect that NLT’s technicians
were originally trained at Biolase or that NLT keeps Waterlase products running better
than the manufacturer.

- 5 -

 

8.0 CONFIDENTIALITY 

	 	 	 	The Parties to this Settlement Agreement shall maintain as strictly confidential and will
continue to maintain the confidentiality of, and not disclose, reveal, publish,
disseminate, or discuss directly or indirectly, to or with any other person or entity the
terms of this Settlement Agreement provided that a Party or counsel may disclose the terms
of this Agreement in the following limited circumstances: (1) pursuant to joint statements
about the Settlement Agreement as indicated below in Section 9.0 or that shall otherwise be
mutually agreed upon by the parties in writing; (2) to comply with applicable law or court
order; (3) to enforce this Agreement; (4) to respond to a lawful demand for information
from a government agency conducting an investigation (i.e., a demand made under compulsory
process or pursuant to other legal mandate); and/or (5) to obtain legal or tax advice.

9.0 JOINT STATEMENTS

	 	9.1.	 	The parties shall not publicly discuss or disclose this Settlement Agreement or its
terms, including but not limited to any dentist, media outlet or website, other than as
stated below or as otherwise mutually agreed upon by the parties in writing:

	 	9.1.1.	 	Upon execution of this Settlement Agreement, NLT and Biolase shall jointly issue and
publish on their respective websites the Press Release at Exhibit A, attached hereto.
Any other communications with any media organization or posting on any website by
either Party shall not deviate from the language contained in Exhibit A, unless
required by applicable law.
	 
	 	9.1.2.	 	Within two (2) business days of the receipt of the Payment, NLT shall send a letter
in the form and using the appropriate language indicated in Exhibit B to the last
known address of each NLT customer who either (a) had purchased a PPS Module from NLT,
or (b) had a service contract on a Biolase Laser as of April 1, 2009. Any other
communications with such customers concerning the terms of this Settlement Agreement
or the results of the Lawsuit shall not deviate from the language contained in Exhibit B.
	 
	 	9.1.3.	 	Any communication between Biolase and any dentist, including but not limited to any
current or former customer of NLT, concerning (a) the assumption of NLT’s service
contracts; (b) the recall, removal or replacement of any PPS Module; or (c) any other
terms of this Settlement Agreement or the results of the Lawsuit shall not deviate
from the language contained in Exhibit C.

10.0 DISMISSAL OF ACTION

	 	 	 	Within three (3) business days of NLT’s (1) receipt of the Payment specified in Section
2.0, and (2) receipt by counsel for NLT of the Stipulation of Dismissal With Prejudice in
the form attached hereto as Exhibit D, signed by or on behalf of

- 6 -

 

	 	 	 	Biolase, NLT agrees to file with the Court the Stipulation of Dismissal With Prejudice
signed by both Parties pursuant to Fed. R. Civ. P. 41(a)(1)(ii).

11.0 GENERAL MUTUAL RELEASES

	 	11.1.1.	 	The mutual releases set forth in this Section shall become effective upon entry of
the Court’s order dismissing the Lawsuit with prejudice. These mutual releases do not
release either Party from the performance of its obligations under this Agreement.
	 
	 	11.1.2.	 	Releases By NLT: For valuable consideration, the sufficiency of which is
hereby acknowledged, NLT hereby releases and forever discharges Biolase and its
employees, officers, directors, agents, representatives, attorneys, insurers, and
assigns of and from any and all claims, acts, debts, demands, actions, causes of
action, suits, dues, sum and sums of money, accounts, reckonings, bonds, covenants,
contracts, controversies, agreements, promises, representations, restitutions, doings,
omissions, variances, damages, and liabilities whatsoever of every name and nature,
(whether known or unknown) existing as of the date of the execution of this Agreement,
including but not limited to any and all claims, counterclaims or causes of action
arising out of or relating to the Lawsuit.
	 
	 	11.1.3.	 	Releases by Biolase: For valuable consideration, the sufficiency of which
is hereby acknowledged, Biolase hereby releases and forever discharges NLT and its
employees, officers, directors, agents, representatives, attorneys, and assigns of and
from any and all claims, acts, debts, demands, actions, causes of action, suits, dues,
sum and sums of money, accounts, reckonings, bonds, covenants, contracts,
controversies, agreements, promises, representations, restitutions, doings, omissions,
variances, damages, and liabilities whatsoever of every name and nature, (whether
known or unknown) existing as of the date of the execution of this Agreement,
including but not limited to any and all claims, counterclaims or causes of action
arising out of or relating to the Lawsuit.
	 
	 	11.1.4.	 	Waiver of Unknown Claims. The Parties acknowledge that each of the Parties has
received independent legal counsel regarding the provisions of California Civil Code
Section 1542, which provides:

	 	 	 	A general release does not extend to claims which the creditor does not
know or suspect to exist in his or her favor at the time of executing the
release, which if known by him or her, must have materially affected his
or her settlement with the debtor.

	 	 	 	The Parties acknowledge and understand that the aforementioned releases are
releases of all known and unknown claims, and hereby expressly waive and relinquish
any rights and benefits which they may have under this code section.

	12.0	 	NO ADMISSION OF LIABILITY

- 7 -

 

	 	 	 	The Parties acknowledge and agree that this Settlement Agreement is a compromise of
disputed claims and that neither this Settlement Agreement nor consideration provided
pursuant to this Settlement Agreement, shall be construed to be an admission or concession
by any Party to this Agreement with respect to any fact, liability or fault.

13.0 REPRESENTATIONS AND WARRANTIES

	 	 	 	Each person whose signature appears hereon represents and warrants that s/he has been duly
authorized and has full authority to execute this Agreement on behalf of any entity or
person on whose behalf this Settlement Agreement is executed. Each Party that executes
this Settlement Agreement represents and warrants that it has not assigned any rights or
obligations relevant to the Settlement Agreement.

14.0 ENTIRE AGREEMENT

	 	 	 	This Settlement Agreement constitutes and contains the entire agreement and understanding
between NLT and Biolase with respect to the subject matter hereof. This Settlement
Agreement supersedes and replaces all prior negotiations and all agreements, proposed or
otherwise, whether written or oral, concerning the subject matter hereof. This is a fully
integrated document. This Agreement can be changed or terminated only upon written consent
of both Parties to the Settlement Agreement.

15.0 VALIDITY/SEVERANCE

	 	 	 	If any provision of this Settlement Agreement is declared by a court of competent
jurisdiction to be illegal, invalid or otherwise unenforceable, then the validity of the
remaining parts shall not be affected thereby, and the invalid portion shall be deemed
stricken from this Agreement.

16.0 GOVERNING LAW AND FORUM SELECTION

	 	 	 	This Settlement Agreement shall be construed, enforced, and governed by the laws of the
State of Indiana, without regard to choice of law principles thereof. If permitted by law,
the Parties agree to seek to resolve all disputes or controversies that may arise hereunder
in the United States District Court for the Southern District of Indiana (subject to any
appeals therefrom), and, in the first instance, to adjudicate their claims before Judge
Sarah Evans Barker or Magistrate Judge Debra McVicker Lynch. If the United States District
Court for the Southern District of Indiana lacks jurisdiction over a dispute or controversy
that may arise hereunder, the parties shall file their claims in Indiana state court.

- 8 -

 

17.0 COOPERATIVE DRAFTING AND CONSTRUCTION

	 	 	 	Each Party to the Settlement Agreement has cooperated in the drafting and preparation of
this Agreement. Hence, this Settlement Agreement shall not be construed against any Party
on the basis that one of the Parties was the principal draftsman. The headings are for the
convenience of the Parties and are not to be used in construing the meaning of any
provision of this Agreement.

18.0 EXECUTION IN COUNTERPARTS AND BY FACSIMILE

	 	 	 	This Settlement Agreement may be signed in counterparts, and shall be deemed executed when
counterparts have been signed by all Parties. True and correct facsimile copies of signed
counterparts may be used in place of the originals for any purpose.

19.0 NO WAIVER OF BREACH

	 	 	 	No waiver of any breach of any term or provision of this Settlement Agreement shall be
construed to be, nor shall be, a waiver of any other breach of this Settlement Agreement.
No waiver shall be binding unless in writing and signed by the Party waiving the breach.

20.0 INDEPENDENT LEGAL ADVICE

	 	 	 	The Parties each acknowledge that each has been advised by its own independently selected
counsel and other advisors in connection with this Settlement Agreement. The parties have
entered into this Agreement solely on the basis of that advice and on the basis of their
own independent investigation of all of the facts, laws and circumstances material to this
Agreement or any provision thereof and not in any manner or to any degree based upon any
statement or omission by any other Party and/or its counsel.

21.0 NOTICES

	 	 	 	Any notice made by any Party to this Settlement Agreement shall be considered proper and
effective only if in writing and mailed by overnight or first class mail addressed as shown
below, or delivered in person or by confirmed electronic transmission. NLT and Biolase
agree to promptly notify the other Party to this Settlement Agreement of any changes in the
names or addresses of persons to be notified.

	 	 	 
	If to National Laser Technology, Inc.:

	 	National Laser Technology, Inc.
	 

	 	Attn: Alan Miller
	 

	 	7405 Westfield Blvd.
	 

	 	Indianapolis, IN 46240

- 9 -

 

	 	 	 
	 

	 	With a copy to:
	 
	 	 
	 

	 	Kendall Millard
	 

	 	BARNES & THORNBURG LLP
	 

	 	11 South Meridian Street
	 

	 	Indianapolis, IN 46204
	 

	 	kmillard@btlaw.com
	 
	 	 
	If to Biolase Technology, Inc.:

	 	Biolase Technology, Inc.
	 

	 	David Mulder
	 

	 	Chief Executive Officer
	 

	 	4 Cromwell
	 

	 	Irvine, CA 92618
	 
	 	 
	 

	 	With a copy to:
	 
	 	 
	 

	 	Mark A. Finkelstein
	 

	 	LATHAM & WATKINS LLP
	 

	 	650 Town Center Drive, 20th Floor
	 

	 	Costa Mesa, California 92626
	 

	 	MARK.FINKELSTEIN@LW.com

	 	 	 	Or to such changed address as shall have been designated by written notice to the Parties.

22.0 SUCCESSORS AND ASSIGNS

	 	 	 	Each Party that executes this Settlement Agreement also agrees that it will not assign its
obligations under this Agreement without the prior written consent of the other Parties to
the Settlement Agreement, which consent shall not be unreasonably withheld or delayed.
Except as otherwise provided herein, this Settlement Agreement shall be binding on and
inure to the benefit of each of the Parties and their respective heirs, personal
representatives, executors, successors and assigns.

23.0 NUMBER; GENDER

	 	 	 	Whenever required by the context, the singular will include the plural, the neuter gender
will include the male gender and female gender, and vice versa.

24.0 ATTORNEYS’ FEES

	 	 	 	In any action that arises out of or relates to this Agreement, the prevailing party shall
be entitled to its reasonable attorneys’ fees and costs.

BY EXECUTING THIS AGREEMENT, EACH OF THE PARTIES TO THIS SETTLEMENT AGREEMENT, AS WELL AS ITS
COUNSEL ACKNOWLEDGES

- 10 -

 

THAT IT HAS READ THIS AGREEMENT AND UNDERSTANDS ITS TERMS AND PROVISIONS.

	 	 	 	 	 
	Dated:  March 25, 2009 	National Laser Technology, Inc.:

 	 
	 	/s/ Alan Miller
 	 
	 	By Alan Miller, CEO 	 
	 	 	 
	 
	Dated:  March  25, 2009 	Biolase Technology, Inc.:

 	 
	 	/s/ David Mulder
 	 
	 	By David Mulder, CEO 	 
	 	 	 

- 11 -

 

	 	 	 	 	 

EXHIBIT A

JOINT PRESS RELEASE

Contact:

For Release:

IRVINE, CA and INDIANAPOLIS, IN – [     ] — BIOLASE Technology, Inc. (NASDAQ: BLTI) and National
Laser Technology, Inc. (NLT) announced today that they have reached a final settlement agreement
resolving the claims and counterclaims in the lawsuit between NLT and Biolase pending in the
Southern District of Indiana concerning NLT’s sale of used Biolase dental lasers. Both parties’
claims will be dismissed with prejudice.

NLT had brought the suit in August 2008 alleging, among other things, that Biolase made false
statements to dentists concerning NLT’s sale of used Biolase lasers and refused to sell laser tips
and other parts to dentists if they did business with NLT in violation of antitrust and unfair
competition laws. Biolase filed counterclaims alleging that NLT infringed Biolase’s copyrights and
trademarks, made false and misleading statements on its website, and modified, sold and serviced
used Biolase lasers without premarket approval from the FDA in violation of unfair competition
laws.

While each party continues to deny the allegations against it, the parties have agreed to resolve
their dispute. The parties are looking forward to selling their respective products.

- 12 -

 

EXHIBIT B

LIMITS OF NLT STATEMENTS TO DENTISTS

Statements to NLT’s service contract customers:

     We are writing concerning your service contract with National Laser Technology, Inc. (NLT).
Biolase, the manufacturer of the Waterlase and Waterlase MD hard tissue dental units, has assumed
the service contract that you currently have with NLT, effective immediately. Biolase will provide
service for your laser for the remaining term of your service contract. If you need to renew your
service at the end of your term, that should be done through Biolase, as NLT is no longer servicing
Biolase lasers.

     Biolase will contact you directly concerning service of your laser. In the meantime, if you
have any service issues or questions, please call Biolase’s global head of services at___.

For those who also bought a PPS Module:

     You have also purchased a PPS Module unit to permit your Waterlase unit to utilize variable
pulses per second. This Module was developed and sold by NLT and not by Biolase, and the FDA had
not granted pre-market approval for this modification prior to its sale. Biolase may therefore
request to remove the Module and replace it with software or another unit with the FDA-cleared
equivalent functionality. If Biolase exercises this option, this removal and replacement would be
handled by Biolase.

For those who bought a PPS Module with no current service contract:

     We are writing concerning the PPS Module that you purchased from National Laser Technology,
Inc. (NLT) to permit your Waterlase unit to utilize variable pulses per second. This Module was
developed and sold by NLT and not by Biolase, the manufacturer of the Waterlase. The FDA had not
granted pre-market approval for this modification prior to its sale.

     Someone from Biolase may contact you directly and request to remove the Module and replace it
with software or another unit with the equivalent functionality. If Biolase exercises this option,
this removal and replacement would be handled by Biolase. If you have any questions, please call
Biolase’s global head of services at ___.

- 13 -

 

EXHIBIT C

LIMITS OF BIOLASE STATEMENTS TO DENTISTS

Statements to NLT’s service contract customers:

     We are writing concerning the service contract on your Biolase laser. Biolase has assumed
your contract with National Laser Technology, Inc. (NLT), effective immediately, and will provide
service for your laser for the remaining term of your service contract. If you need to renew your
service at the end of your term, that should be done through Biolase, as NLT is no longer servicing
Biolase lasers.

     If you have any service issues or questions, please call Biolase’s global head of services at
                                        .

For those who also bought a PPS Module:

     You have also purchased a PPS Module unit to permit your Waterlase unit to utilize variable
pulses per second. This Module was developed and sold by NLT and not by Biolase, and the FDA had
not granted pre-market approval for this modification prior to its sale. We request that you
permit us to remove the Module and replace it with software or another unit with the FDA-cleared
equivalent functionality. This removal and replacement would be handled by us.

For those who bought a PPS Module with no current service contract:

     We are writing concerning the PPS Module that you purchased from National Laser Technology,
Inc. (NLT) to permit your Waterlase unit to utilize variable pulses per second. This Module was
developed and sold by NLT and not by Biolase, the manufacturer of the Waterlase. The FDA had not
granted pre-market approval for this modification prior to its sale.

     We request that you permit us to remove the Module and replace it with software or another
unit with the FDA-cleared equivalent functionality. This removal and replacement would be handled
by us. If you have any questions, please call Biolase’s global head of services
                                        .

- 14 -

 

EXHIBIT D

UNITED STATES DISTRICT COURT

SOUTHERN DISTRICT OF INDIANA

INDIANAPOLIS DIVISION

	 	 	 	 	 	 	 	 	 
	NATIONAL LASER TECHNOLOGY, INC.,	 	 	)	 	 	 
	 

	 	 	 	 	)	 	 	 
	 

	 	Plaintiff/Counter-defendant,
	 	 	)	 	 	 
	 

	 	 	 	 	)	 	 	 
	 

	 	v.
	 	 	)	 	 	Cause No.: 1:08-CV-01123-SEB-DML
	 

	 	 	 	 	)	 	 	 
	BIOLASE TECHNOLOGY, INC.	 	 	)	 	 	 
	 

	 	 	 	 	)	 	 	 
	 

	 	Defendant/Counter-plaintiff.
	 	 	)	 	 	 

JOINT STIPULATION OF DISMISSAL WITH PREJUDICE

     Pursuant to Federal Rule of Civil Procedure 41(a)(1), all parties to the above action hereby
stipulate that this action and all claims and counter claims should be dismissed with prejudice
pursuant to the Settlement Agreement reached by the parties. The Court shall retain jurisdiction
to enforce the terms of the Settlement Agreement.

     Dated this ___ day of ___, 2009.

	 	 	 	 	 
	 	Respectfully submitted,

 	 
	 	/s/   DRAFT
 	 
	 	Todd G. Vare (#18458-49) 	 
	 	Kendall Millard (#25430-49)

Hamish S. Cohen (#22931-53)

BARNES & THORNBURG LLP

11 South Meridian Street

Indianapolis, Indiana  46204

Telephone: (317) 236-1313
 	 

	 	 	 	 	 
	 	Attorneys for Plaintiff,

National Laser Technology, Inc.

 	 
	 	/s/   DRAFT
 	 
	 	Mark A. Finkelstein 	 
	 	LATHAM & WATKINS LLP

650 Town Center Drive, 20th Floor

Costa Mesa, California 92626 	 

- 15 -

 

	 	 	 	 	 

Eric J. McCarthy

Brent W. Johnson

LATHAM & WATKINS LLP

555 Eleventh Street, NW, Suite 1000

Washington, D.C. 20004

Alfred C. Pfeiffer, Jr.

LATHAM & WATKINS LLP

505 Montgomery Street, Suite 2000

San Francisco, California 94111-6538

Renee J. Mortimer

HINSHAW & CULBERTSON LLP

322 Indianapolis Boulevard, Suite 201

Schererville, IN 46375

Alan Greene

HINSHAW & CULBERTSON LLP

222 N. LaSalle Street

Suite 3000

Chicago, IL 60601

Counsel for Biolase Technology, Inc.

- 16 -exv10w6

Exhibit 10.6

Biolase Technology, Inc.

4 Cromwell

Irvine, California 92618

April 3, 2009

David M. Mulder

c/o Biolase Technology, Inc.

4 Cromwell

Irvine, California 92618

			
	Re:	 	Amendment No. 2 to Employment Agreement

Dear Mr. Mulder:

This letter agreement shall serve to amend that certain Employment Agreement, dated April 29, 2008,
as amended by that certain letter agreement, dated March 4, 2009 (the “Employment Agreement”), by
and between Biolase Technology, Inc. (the “Company”) and David M. Mulder (the “Executive”).

Effective as of March 5, 2009, the parties agree as follows:

1. The first sentence of Section 3.A. of the Employment Agreement is hereby deleted in its entirety
and replaced with the following:

“Executive shall be paid a base salary at the annual rate of not less than TWO
HUNDRED FIFTY THOUSAND dollars ($250,000) per annum (hereinafter “Base Salary”)
during the Employment Period.”

2. The first sentence of Section 4.A. of the Employment Agreement is hereby deleted in its entirety
and replaced with the following:

“For each full calendar year during the Employment Period, Executive may earn an
annual Performance Bonus of up to ONE HUNDRED FIFTY THOUSAND dollars ($150,000)
(the “Performance Bonus Target”) based on achievement of Performance Bonus
criteria.”

3. The second sentence of Section 5.C. of the Employment Agreement is hereby deleted in its
entirety and replaced with the following:

 

 

“For purposes of this Section 5.C, “Relocation Expenses” shall mean (i) travel,
lodging and meal expenses for Executive and his spouse and children for house
hunting trips or relocation to Executive’s new principal residence, (ii) expenses
for moving the household goods, personal effects and automobiles of Executive and
his spouse and children from Executive’s current principal residence to his new
principal residence, (iii) brokerage commission expenses incurred by Executive in
connection with the sale of Executive’s current principal residence, and (iv)
amounts calculated in accordance with Section 5.F. below, provided the expenses
described in clause (i), (ii) or (iii) are directly related to the relocation of
Executive’s principal residence in connection with Executive’s commencement of
employment with the Company. The total amount of Relocation Expenses reimbursed by
the Company shall not exceed FIFTY THOUSAND dollars ($50,000), and such Relocation
Expenses shall be reimbursed only if incurred by Executive not later than December
31, 2009.”

4. The following new Section 5.F. is hereby added to the Employment Agreement:

“F. From the Effective Date until December 31, 2009, Executive shall be provided
with an apartment for Executive’s personal use in Irvine, California, which
apartment shall be reasonably acceptable to the Company and Executive and with a
rental rate of not more than $2,100 per month; provided however, $1,050 of rent
that is incurred each month by the Company shall be treated as Relocation Expenses
pursuant to Section 5.C. above and shall reduce the total amount of Relocation
Expenses available to the Executive as provided for in such section.”

This letter agreement amends certain terms and conditions of the Employment Agreement. All other
terms and conditions of the Employment Agreement that are not modified by this letter agreement are
hereby ratified and confirmed in all respects, and shall remain in full force and effect. Should
there be any conflict between the terms and conditions contained in this letter agreement and the
Employment Agreement, the terms and conditions of this letter agreement shall govern and control.

Please acknowledge your agreement to the foregoing terms and conditions by countersigning this
letter agreement in the space provided below.

Very truly yours,

	 	 	 	 	 
	 	BIOLASE TECHNOLOGY, INC.

 	 
	 	By:  	/s/ James R. Largent
 	 
	 	 	     Name:  	James R. Largent 	 
	 	 	     Title:  	Chairman, Compensation Committee 	 

2

 

	 	 	 	 	 
	 	ACKNOWLEDGED AND AGREED:

 	 
	 	/s/ David M. Mulder
 	 
	 	David M. Mulder 	 
	 	 	 
	 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]